S Morinaga
Overview
Explore the profile of S Morinaga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
179
Citations
748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miwa S, Nojima T, Alomesen A, Ikeda H, Yamamoto N, Nishida H, et al.
Clin Transl Oncol
. 2021 Feb;
23(8):1620-1629.
PMID: 33635466
Background: Although immunotherapy is thought to be a promising cancer treatment, most patients do not respond to immunotherapy. In this post hoc analysis of a phase 1/2 study, associations of...
2.
Tamagawa H, Oshima T, Numata M, Yamamoto N, Shiozawa M, Morinaga S, et al.
Eur J Surg Oncol
. 2013 Mar;
39(6):655-61.
PMID: 23523318
Background: We evaluated the methylation patterns of histone H3 lysine 27 (H3K27), H3 lysine 36 (H3K36) and the expression of H3K27 methylase EZH2 in patients with colorectal carcinomas with metachronous...
3.
Watanabe T, Morinaga S, Akaike M, Numata M, Tamagawa H, Yamamoto N, et al.
Eur J Surg Oncol
. 2012 Sep;
38(11):1051-7.
PMID: 22959167
Background: To search for biomarkers identifying pancreatic cancer patients likely to benefit from adjuvant gemcitabine chemotherapy, we investigated the status of several histone modifications in pancreatic tumors and their relationship...
4.
Nishiyama T, Morinaga S, Nagayama K
Rev Sci Instrum
. 2009 Apr;
80(3):033904.
PMID: 19334931
This paper describes a novel method for the fabrication of a thin film deposited on an appropriate substrate having a continuous composition gradient. The composition gradient was achieved by a...
5.
Narimatsu H, Kami M, Kato D, Matsumura T, Murashige N, Kusumi E, et al.
Transpl Infect Dis
. 2007 Feb;
9(1):11-5.
PMID: 17313465
Although foscarnet is a promising alternative for the treatment of cytomegalovirus (CMV) infection, its toxicity can be significant in patients with advanced age. We retrospectively reviewed medical records of 123...
6.
Narimatsu H, Kami M, Hara S, Matsumura T, Miyakoshi S, Kusumi E, et al.
Bone Marrow Transplant
. 2005 Jul;
36(6):517-23.
PMID: 16025150
Thrombotic microangiopathy (TMA) is a significant complication after hematopoietic stem-cell transplantation (HSCT); however, there is little information on it following reduced-intensity cord blood transplantation (RI-CBT). We reviewed the medical records...
7.
Narimatsu H, Wake A, Miura Y, Tanaka H, Matsumura T, Takagi S, et al.
Bone Marrow Transplant
. 2005 Jul;
36(6):555-6.
PMID: 16007108
No abstract available.
8.
Maeda T, Kusumi E, Kami M, Kawabata M, Le Pavoux A, Hara S, et al.
Bone Marrow Transplant
. 2004 Nov;
35(1):91-7.
PMID: 15516933
Allogeneic hematopoietic stem cell transplantation (allo-SCT) recipients are prone to infections. The incidences of mycobacterial infections after allo-SCT in several case series vary from less than 0.1-5.5%. However, no study...
9.
Kusumi E, Arakawa A, Kami M, Kato D, Yuji K, Kishi Y, et al.
Leukemia
. 2004 Apr;
18(6):1138-9.
PMID: 15085156
No abstract available.
10.
Kusumi E, Kami M, Yuji K, Hamaki T, Murashige N, Hori A, et al.
Bone Marrow Transplant
. 2004 Feb;
33(7):697-702.
PMID: 14755317
To evaluate the feasibility of reduced intensity stem cell transplantation (RIST) with bone marrow from a matched unrelated donor (MUD), we retrospectively investigated 20 patients with hematological disorders who received...